Ginkgo Bioworks 通过反向收购上市引起市场广泛关注，不仅仅是因为Ginkgo将迄今为止最大的SPAC交易之一，更重要的是，Ginkgo Bioworks背后拥有超豪华的 ...

9月，Ginkgo完成SPAC合并交易并登陆纽交所，公司市值迅速超过200亿美元。

SPAC繁荣期间 全球IPO筹资额与上市数量创下纪录 根据Refinitiv的数据，全球企业今年通过IPO筹集了约2480亿美元，创历史新高，其中包括所谓的SPACs的 ...

Ginkgo Bioworks will go public via SPAC merger as other cleantech SPACs face short-seller attacks Deal values Ginkgo at more than $17 billion; short sellers shave PureCycle and Danimer stock prices ...

The Ginkgo Bioworks IPO brings opportunity in the engineered biology market. And the company decided to offer Ginkgo Bioworks stock via SPAC Soaring Eagle.

Synthetic-biology company Ginkgo Bioworks is getting set to go public by merging with Soaring Eagle Acquisition Corp. (NASDAQ: SRNG), a special purpose acquisition company ("SPAC"). At a market ...

Soaring Eagle Acquisition (SRNG) is set to take Ginkgo Bioworks public in a massive SPAC merger. To me, Ginkgo Bioworks seems like a high risk/reward, long-term investment. See why.

Ginkgo's $17.5 Bln SPAC Deal Presupposes Success May 12, 2021 6:45 AM ET DNA 2 Comments 4 Likes Lipper Alpha Insight 2.76K Follower s ...

Synthetic biology pioneer Ginkgo Bioworks said today it will become a public company through a $17.5 billion merger with a special purpose acquisition company (SPAC) that is expected to provide up ...

Ginkgo Bioworks, a company whose cell engineering work can be found in products ranging from food ingredients to vaccines, is going public in a SPAC deal that values it at $15 billion. The merger ...

Ginkgo Bioworks, a synthetic biology company now valued at around $15 billion, begins trading on the New York Stock Exchange today. Ginkgo’s market debut is one of the largest in biotech history.